SCHEMBL24625968

SCHEMBL24625968

NCCNC(=O)CCN(CCC(=O)NCCN)CCN(CCC(=O)NCCN)CCN(CCC(=O)NCCN)CCC(=O)NCCN

nearest known ligand 0.92

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 1/20 0.37
HIF1A Q16665 1/20 0.37
TET2 Q6N021 1/20 0.37
DOHH Q9BU89 1/20 0.37
DNM1 Q05193 2/20 0.35
LMNA P02545 2/20 0.35
GAA P10253 2/20 0.35
KDM4E B2RXH2 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TSHR P16473 3/20 0.33
CYP2C19 P33261 2/20 0.33
ALDH1A1 P00352 2/20 0.33
SLC6A5 Q9Y345 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
FAAH O00519 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10194547 1.00 KDM4A (0.37) KDM4AHIF1ATET2DOHHDNM1
SCHEMBL16984940 1.00 KDM4A (0.37) KDM4AHIF1ATET2DOHHDNM1
SCHEMBL12219612 0.98 KDM4A (0.38) KDM4AHIF1ATET2DOHHDNM1
Poly(Amidoamine)Dendrimer SCHEMBL13964588 0.96 DNM1 (0.37) KDM4AHIF1ATET2DOHHDNM1
SCHEMBL13374199 0.96 KDM4A (0.36) KDM4AHIF1ATET2DOHHDNM1
SCHEMBL8239576 0.96 DNM1 (0.37) KDM4AHIF1ATET2DOHHDNM1
SCHEMBL17126969 0.94 KDM4A (0.36) KDM4AHIF1ATET2DOHHDNM1
SCHEMBL16985018 0.92 NAAA (0.34) KDM4AHIF1ATET2DOHHDNM1
SCHEMBL13913072 0.92 CA1 (0.37) KDM4AHIF1ATET2DOHHDNM1
SCHEMBL12315040 0.92 KDM4A (0.42) KDM4AHIF1ATET2DOHHDNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220220065-A1 ADDITIVE FOR ELECTROPLATING SOLUTIONS, ELECTROPLATING SOLUTION, ELECTROPLATING METHOD AND NOVEL COMPOUND ADEKA CORPORATION (JP) 2022-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220065-A1 ADDITIVE FOR ELECTROPLATING SOLUTIONS, ELECTROPLATING SOLUTION, ELECTROPLATING METHOD AND NOVEL COMPOUND SLC26A3, CLCN2, AP1M1 KDM4A 3932/4885HIF1A 3639/4885TET2 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.